Gangopadhyay Kalyan Kumar, Sinha Binayak, Ghosal Samit
Department of Diabetes & Endocrinology, Fortis Hospital, Peerless Hospital, 730, Eastern Metropolitan Bypass, Kolkata, India.
Department of Diabetes & Endocrinology, Fortis Hospital, AMRI Hospital, 730, Eastern Metropolitan Bypass, 700107, Kolkata, India.
Diabetes Metab Syndr. 2020 Sep-Oct;14(5):1413-1418. doi: 10.1016/j.dsx.2020.07.040. Epub 2020 Jul 25.
As the Coronavirus disease 2019 (COVID-19) pandemic unravels rapidly, there is a glut of confusing and divergent scientific information emanating from differing sources, including the Indian National Task Force for COVID-19. Thus, a web-based survey was conducted to decipher the approach of Indian doctors to the various options for treatment of COVID-19.
A web-based questionnaire among one lakh doctors across India through email and social media was circulated. After data quality and internal validation, 826 responses were included for analysis. Basic demographic and comparative analysis were performed using the Python3.8.2 software (Windows 10 64 bit, USA).
Amongst all the states of India most respondents hailed from the top ten affected states. Overall 76.15% of doctors would either prescribe or consider prescribing hydroxychloroquine (HCQ) as prophylaxis for health-care providers (HCP). Doctors with experience of managing COVID-19 were more likely to advocate use of HCQ as prophylaxis for HCP (χ2 = 4.357, P = 0.037). Intensivists were more likely to advocate HCQ as prophylaxis (χ2 = 14.588, P < 0.001) as well as for management of mild to moderate COVID-19 (χ2 = 3.91, P = 0.048). In COVID-19, 65.8% doctors overwhelmingly preferred using anti-viral agents in severe cases, continuing ACEi/ARB (60.9%), and routinely screening for COVID-19 as a pre-operative strategy (73.85%).
Indian doctors are largely following the scientific guidance provided by Indian National Task Force for COVID-19 and would consider prescribing HCQ as prophylaxis for COVID-19. They would also consider using it in mild to moderate COVID-19.
随着2019年冠状病毒病（COVID-19）大流行迅速蔓延，包括印度COVID-19国家特别工作组在内的不同来源产生了大量令人困惑且相互矛盾的科学信息。因此，开展了一项基于网络的调查，以解读印度医生对COVID-19各种治疗方案的看法。
通过电子邮件和社交媒体向印度各地的10万名医生发放了一份基于网络的问卷。在进行数据质量和内部验证后，纳入826份回复进行分析。使用Python3.8.2软件（美国Windows 10 64位）进行基本人口统计学和比较分析。
在印度所有邦中，大多数受访者来自受影响最严重的前十个邦。总体而言，76.15%的医生会开具或考虑开具羟氯喹（HCQ）作为医护人员（HCP）的预防用药。有COVID-19管理经验的医生更倾向于主张将HCQ用作HCP的预防用药（χ2 = 4.357，P = 0.037）。重症监护医生更倾向于主张将HCQ用作预防用药（χ2 = 14.588，P < 0.001）以及用于轻度至中度COVID-19的治疗（χ2 = 3.91，P = 0.048）。在COVID-19治疗中，65.8%的医生绝大多数倾向于在重症病例中使用抗病毒药物，继续使用血管紧张素转换酶抑制剂/血管紧张素Ⅱ受体阻滞剂（60.9%），并将COVID-19常规筛查作为术前策略（73.85%）。
印度医生在很大程度上遵循印度COVID-19国家特别工作组提供的科学指导，并会考虑开具HCQ作为COVID-19的预防用药。他们也会考虑在轻度至中度COVID-19中使用该药。
